MARKET

IRWD

IRWD

Ironwood
NASDAQ
4.170
+0.330
+8.59%
Opening 15:53 06/26 EDT
OPEN
3.810
PREV CLOSE
3.840
HIGH
4.170
LOW
3.790
VOLUME
2.13M
TURNOVER
--
52 WEEK HIGH
5.78
52 WEEK LOW
0.6601
MARKET CAP
686.44M
P/E (TTM)
7.13
1D
5D
1M
3M
1Y
5Y
1D
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
NASDAQ · 10h ago
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
NASDAQ · 1d ago
10 small-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 2d ago
Weekly Report: what happened at IRWD last week (0615-0619)?
Weekly Report · 4d ago
Ironwood Pharma Shareholders Reaffirm Board and Governance Structure
TipRanks · 06/18 20:32
Ironwood Pharmaceuticals shareholders approve 10 million-share increase to equity incentive plan
PUBT · 06/18 20:15
Ironwood Pharma Director Julie McHugh disposes of 21,571 shares worth $80,449.83
PUBT · 06/17 20:42
These small-cap healthcare stocks pair revenue growth with attractive valuations
Seeking Alpha · 06/17 11:02
More
About IRWD
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.

Webull offers Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ: IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.